Baird Melissa

COO Melissa Baird sold 33,333 shares at blended average $56.02; stock now at $64.00 (+14.2% above sale prices)

Melissa Baird, COO of Hims & Hers, executed 4 separate sales totaling 33,333 shares for $1,867,376.22 on 2025-05-12, reducing her holdings from 838,416 to 805,083 shares (a -4.0% reduction). The blended average sale price of $56.02 stands below the current market price of $64.00, indicating the stock has appreciated since the transaction. At HIMS specifically, Baird's recent trading pattern shows 3 prior sells on 2025-04-09 with measured 30-day returns of +77.8%, +82.0%, and +92.9%, suggesting those earlier sales preceded substantial near-term gains. Her cross-ticker track record shows a 55.56% well-timed rate on 20 prior sells, indicating moderate success at timing exits, though the sample reflects prior outperformance in a different context. The company's fundamentals show strong growth (annual revenue growth of +69.3%) and positive profitability ($49,485,000.00 net income on $586,010,000.00 revenue), but a notably high P/E of 110.34 reflects elevated valuation expectations.

COO Melissa Baird sells 33,333 shares for $859.3K at avg $25.78 on 2025-04-21, amid -61.1% decline from 52-week high and -28.6% 30-day drop

Melissa Baird, Chief Operating Officer, executed two separate sales totaling 33,333 shares for $859,256.11 on 2025-04-21, reducing her holdings by 4.0% to 805,083 shares post-transaction. The sales occurred at an average price of $25.78, while the stock currently trades at $26.71, well down from its 52-week high of $68.74 (presently -61.1% from peak) and down 28.6% over the prior 30 days. Across Baird's cross-ticker insider trading history, her prior sells have achieved an 85.71% well-timed rate over 90 days, though measurable outcomes for her five prior HIMS trades remain pending. Against a backdrop of strong HIMS fundamentals—revenue of $401,556,000.00 in the latest quarter and net income of $75,588,000.00—this sale is a material reduction by the COO during a period of significant stock weakness.

COO Baird Melissa sold 33,337 shares for $910.7K on 2025-04-09; stock down 61.0% from 52-week high

Melissa Baird, Chief Operating Officer of Hims & Hers, executed 4 separate sales totaling 33,337 shares for $910,687.46 on 2025-04-09, reducing her holdings by -4.0%. The transaction prices ranged from $25.82 to $29.23 across the four separate sales. The stock currently trades at $26.81, down 61.0% from its 52-week high of $68.74 and down 22.8% over the prior 30 days. Baird has sold shares on this ticker in each of the prior five tracked transactions (all on 2025-03-26); the pattern shows consecutive insider sales despite sharp recent price declines. The company reports strong fundamentals with annual revenue growth of +69.3%, $401.6M in latest quarterly revenue, and $75.6M in net income, yet the stock has retreated significantly from recent highs.

COO Melissa Baird sold 67,687 shares for $2,358,144.87 across 5 separate sales on 2025-03-26, blended average $34.84

Melissa Baird, Chief Operating Officer, executed 5 separate sales totaling 67,687 shares (67.7K shares) for $2,358,144.87 ($2.4M) at prices ranging from $33.57 to $37.35, reducing her holdings by 8.3%. The stock now trades at $31.92, down 53.6% from its 52-week high of $68.74 and down 19.9% over the past 30 days, though up 20.2% over 90 days. Her prior sales at HIMS on 2025-02-12 all showed negative 30-day returns (ranging from -23.6% to -28.4%), suggesting recent trades at this ticker have experienced near-term declines. The company's fundamentals remain strong with revenue of $401.6M, net income of $75.6M, and annual revenue growth of 69.3%, though the stock's elevated P/E of 55.03 may reflect lofty valuation relative to current earnings.

COO Melissa Baird sold 67,687 shares for $3,026,624.13 on 2025-02-12 at blended avg $44.71/share

Melissa Baird, Chief Operating Officer, executed 4 separate sales totaling 67,687 shares for $3,026,624.13 on 2025-02-12, reducing her holdings by 8.7% to 706,872 shares post-transaction. The sales occurred at prices ranging from $43.37 to $46.27, with a blended average of $44.71, substantially below the current price of $60.47. Her cross-ticker track record shows 20 prior open-market sells with an average 90-day return of +99.4% and a well-timed rate of 0.00%, indicating her prior sales have generally preceded stock appreciation rather than decline. At HIMS specifically, she has executed 5 recent sales in late January with outcomes not yet measurable. The company is on a 30-day gain of +117.0% and 90-day gain of +213.0%, and despite recent profitability, the timing of a large insider liquidation at stock prices well below current levels may warrant observation of her transaction pattern at this holding.

COO Melissa Baird sells 67,687 shares ($1,986,730.70) across 6 transactions at HIMS, retaining 706,872 shares post-sale.

Melissa Baird, Chief Operating Officer at Hims & Hers Health, Inc., executed 6 separate sales totaling 67,687 shares for $1,986,730.70 on 2025-01-21, with prices ranging from $28.57 to $29.72 and a blended average of $29.35. This represents an 8.7% reduction in her pre-transaction holdings of 774,559 shares, leaving her with 706,872 shares post-transaction. The current price of $30.89 is 9.8% below the 52-week high of $34.23, and the stock is up 9.7% over 30 days and 42.2% over 90 days from the transaction date. Within her same-ticker history at HIMS, Baird's prior 5 trades (conducted in November–December 2024) showed mixed results: two December 10 sales posted 30-day losses of -17.2% and -15.8%, while two November 18 sales posted 30-day gains of +34.1% and +39.4%; no 90-day outcomes are yet measurable for those trades. Her cross-ticker track record across 20 prior open-market sales shows an average 90-day return of +70.5% and a well-timed rate of 0.00%, indicating her prior sells at other tickers have generally occurred before price increases rather than declines. The company reported strong fundamentals with $401.6M in latest quarterly revenue and $75.6M in net income, though it was unprofitable on a full-year basis, revealing a recent inflection to profitability.

COO Baird sells 85,561 shares at $30.55–$31.98 ($2.7M) after 4 recent sells; stock near 52-week highs (+81.6% in 90 days).

Melissa Baird, COO of HIMS, executed 3 separate sales totaling 85,561 shares on 2024-12-10 at a blended average price of $31.01, generating $2,653,128.90. This follows 4 prior HIMS sales just 22 days earlier on 2024-11-18, indicating a sustained pattern of share reduction. The timing context is notable: the stock has risen 81.6% over 90 days and 12.7% over 30 days, trading within 12.1% of its 52-week high. While Baird's cross-ticker track record shows a 21.43% well-timed sell rate historically, her same-ticker history at HIMS shows 0 of 0 prior sells were well-timed at the 90-day mark. This concentrated selling activity during a period of strong stock appreciation warrants monitoring to understand if it reflects liquidity needs, estate planning, or other non-conviction-driven factors.

COO Melissa Baird sells 58,750 shares for $1.2M as stock gains 6.2% in 30 days; prior sales at HIMS all well-timed

Melissa Baird, Chief Operating Officer, executed 4 separate sales totaling 58,750 shares for $1,236,363.80 at a blended average price of $21.04 on 2024-11-18, reducing her holdings by 8.5% to 630,166 shares. Her recent trades at HIMS show a consistent pattern of well-timed exits: all 5 prior trades at this ticker posted 30-day gains ranging from +19.6% to +22.7%, suggesting the COO has demonstrated accuracy in selling ahead of favorable price movements. The current stock price of $23.53 sits -15.6% from the 52-week high of $27.88, but has risen 6.2% over the past 30 days and 42.0% over 90 days, indicating a sustained recovery phase. Against a backdrop of strong quarterly fundamentals—revenue of $401,556,000.00, net income of $75,588,000.00, and annual revenue growth of +65.5%—the sale reflects neither distress nor contrarian positioning, but rather execution aligned with her demonstrated pattern of operational timing.

COO Melissa Baird sells 58,750 HIMS shares (58.8K) for $1.1M at $19.57-$19.58 on 2024-10-07; stock now at $18.75.

Melissa Baird, Chief Operating Officer of Hims & Hers Health, Inc., executed 2 separate sales totaling 58,750 shares for $1,149,625.29 at blended average price $19.57, reducing her holdings by 8.5% to 630,166 shares. The current stock price of $18.75 is 24.4% below the 52-week high of $24.79, though the stock is up 37.4% over the prior 30 days and down 7.2% over 90 days. Baird's cross-ticker track record across all open-market trades shows 20 prior sells with a 90d well-timed rate of 100.00%, but her same-ticker history at HIMS (5 prior sales in early September) has not yet produced measurable 90-day outcomes; near-term post-sale returns on those September trades range from +18.2% to +22.7% at the 30-day mark. The company reported revenue of $315,648,000.00 for the latest quarter with annual revenue growth of +65.5%, though it remains unprofitable on a full-year basis. This sale represents a discrete insider reduction timed within the 52-week price decline context, warranting routine disclosure monitoring.

Baird (COO) sold 35.4K shares for $513.5K across 6 transactions (Sept 3–5 at $14.40–$14.65); holds 585.8K post-sale.

Melissa Baird, Chief Operating Officer, executed 6 separate sales totaling 35,382 shares for $513,487.14 over three days (September 3–5, 2024) at prices between $14.40 and $14.65, reducing her holdings by 5.7%. The timing coincides with a steep recent decline: the stock is down 41.8% from its 52-week high and has fallen 30.6% over the past 90 days and 14.5% in the last 30 days. Her prior sales at HIMS show a pattern of post-transaction declines (all five recent same-ticker sales in early August registered 30-day negative returns ranging from -13.1% to -17.5%), though longer-term outcomes remain unmeasured. The company's growth metrics remain strong (revenue up 65.5% annually), but it remains unprofitable on a full-year basis, introducing potential macro or operational uncertainty. The multi-day execution and concentrated dollar amount ($513.5K) against a backdrop of significant recent price deterioration warrant investor attention to whether this reflects portfolio rebalancing pressures or signals emerging operational or valuation concerns.